Home » Services » Training
Training - Drug Discovery Course 2013

PLEASE NOTE: Registration for this course is now CLOSED.


The Drug Discovery Course will provide you with insight into the basic principles of the process generating new medicine candidates. You will learn how the critical path of drug discovery is designed and what are the pitfalls and potential hurdles which will prevent you of generating a promising candidate. The course will include the following modules:


Day 1 (Monday, 9 September 2013, 9:00 am – 4:00 pm)

Introduction to Drug Discovery: Past – Present – Future?

(Alex Matter, ETC)


Target Identification and Validation (David Lane, A*STAR p53 lab)

The Way to Novel Drug Molecules (Michael Entzeroth, ETC)


Day 2 (Monday, 16 September 2013, 9:00 am – 5:00 pm)

Protecting your Intellectual Property in Drug Discovery

     (Victoria Lovatt, Aslan Pharmaceuticals) - Part 1

Protecting your Intellectual Property in Drug Discovery

     (Victoria Lovatt, Aslan Pharmaceuticals) - Part 2

Hit-to-Lead Process and Lead Optimization (Thomas Keller, ETC)

Compound Libraries and Molecular Modeling (Shahul Nilar, NITD)


Day 3 (Monday, 23 September 2013, 9:00 am – 5:00 pm)

Assay Development and Screening (Angela Dunne, GSK)

Pharmacokinetics (Edward Browne, GSK)

Translational Sciences (Hannes Hentze, MSD)

Peptide-based drugs: Design and Development (Brian Chia, ETC)


Day 4 (Monday, 30 September 2013, 9:00 am – 4:15 pm)

In-vivo Drug Evaluation (Ian Gray, Takeda Singapore)

Preclinical Development (Brian Dymock, NUS)

Preparing for Regulatory Submission (Tan Lisa, HSA)


Location for all four modules will be at:

Biopolis, Aspiration Theatre, Matrix Level 2M


The course has been designed for scientists with interest to bring their discoveries from the bench to the bedside in the clinics. For all four modules a nominal fee of SGD 400 for scientists and SGD 100 (incl. GST) will be charged for students without monthly salary (please indicate). Each participant will receive a certificate at the end of the course, provided that all modules have been attended and completed.


As limited space is available, the organizers reserve themselves the right to select participants, based on their CVs submitted. Successful candidates will be informed, invoiced and confirmed after receipt of the payment of the course fees. Candidates who have not been successful will have the chance to enroll in the 2014 course.





Trainers will include:

  • Professor Alex Matter, M.D.
    CEO, Experimental Therapeutics Centre, A*STAR, Singapore and Chairman, Esperanza Medicines Foundation, Basel, Switzerland


  • Michael Entzeroth, Ph.D.
    Deputy Director – Global Alliances, Experimental Therapeutics Centre, A*STAR, Singapore


  • Victoria Lovatt, Ph.D.
    Patent Counselor, Abbott, Singapore


  • Professor Sir David Lane FRS, FRSE, FMedSci, FRCP
    A*STAR Chief Scientist, Singapore


  • Shahul Nilar, Ph.D.
    Investigator III, Novartis Institute for Tropical Diseases, Singapore


  • Thomas Keller, Ph.D.
    Deputy Director – Medicinal Chemistry, Experimental Therapeutics Centre, A*STAR, Singapore


  • Ian Gray, Ph.D.
    Vice President of Research, Takeda Singapore